Market Overview
Size, mix, and extracorporeal demand
- Brevintel analysis estimates the membrane oxygenators market at USD 133.8 million in 2025 ($134M), reaching USD 167.5 million by 2035 ($168M) at a 2.4% CAGR from 2026 to 2035 (2026-2035).
- A 2026 checkpoint of USD 135.9 million sits between the 2025 base and the 2035 outlook.
- This follows an approximately 1.6% CAGR during 2022-2024, indicating measured acceleration rather than a return to pandemic-era utilization.
- Abbott led with over 18% market share in 2025; Abbott, LivaNova, Medtronic, MicroPort, and NIPRO collectively held 40%.
- Hollow fiber platforms, particularly polymethylpentene (PMP) membranes, support longer-duration ECMO because a dense outer layer limits plasma leakage associated with earlier microporous designs.
- Flat sheet devices remain relevant in shorter-duration extracorporeal circulation and selected specialized circuits, but lower projected growth reflects the shift toward long-duration ECMO-capable hollow fiber systems.
- Respiratory failure, cardiac support, and extracorporeal cardiopulmonary resuscitation (ECPR) define the principal demand pool.
- The ELSO Registry reported 154,568 ECMO runs from 2009 to 2022 across 780 reporting centers, with adult annual runs increasing from 851 in 2009 to 17,975 in 2021.
Program intensity versus procedure volume
- Brevintel analysis indicates progression from USD 133.8 million in 2025 to USD 167.5 million in 2035 will be governed more by expansion and utilization intensity of qualified ECMO programs than by broad-based procedure volume.
- Oxygenators are single-use, clinically critical components, but consumption is constrained by staffing, perfusion capability, ICU capacity, and reimbursement for a resource-intensive care pathway.
- The World Health Organization estimates that cardiovascular diseases caused 19.8 million deaths in 2022, equivalent to approximately 32% of global deaths.
- A 2025 global burden assessment reported 626 million prevalent cardiovascular disease cases and 19.2 million deaths in 2023.
- The LungSAFE study (2016) found that ARDS represented 10.4% of ICU admissions and 23.4% of mechanically ventilated patients across its international cohort.
- U.S. estimates place ARDS incidence at 64.2-78.9 cases per 100,000 person-years, with sepsis, pneumonia, and shock as important associated risk factors (2006-2014).
- The Global Observatory on Donation and Transplantation reported 173,727 solid-organ transplants worldwide in 2024, including 10,287 heart transplants and 8,236 lung transplants.
- ECPR protocol development, cardiac shock management, and new ECMO-center formation provide incremental demand, while regulatory qualification and the total cost of ECMO limit adoption outside advanced hospitals.
Market Dynamics
Clinical drivers
- Cardiovascular disease creates the largest long-term clinical base for cardiac ECMO and oxygenator use in cardiogenic shock, post-cardiotomy support, and bridge-to-decision care.
- Rising disease prevalence does not translate automatically into ECMO utilization; it increases the number of patients reaching tertiary cardiac programs when conventional support is insufficient.
- ECMO program expansion converts clinical capability into recurring oxygenator demand, with utilization intensity as important as the number of active centers because longer support episodes may require circuit-component replacement.
- Pediatric annual runs increased from 1,154 in 2009 to 2,394 in 2021, while neonatal respiratory ECMO survival to hospital discharge was 68.5%.
- Pediatric ECMO outcomes in South Korea improved over a 10-year observation period, indicating maturation of specialized programs.
- Neonatal and pediatric ECMO requires low-priming-volume circuits and age-specific device configurations that are less substitutable than scaled-down adult products.
- Comparative evidence has associated ECPR with improved survival and neurological outcomes versus conventional CPR in selected cardiac-arrest settings.
- Heart and lung transplant perioperative pathways may require extracorporeal circulation or temporary ECMO, making specialized-center purchasing commercially valuable despite limited absolute volume.
Constraints
- The U.S. Food and Drug Administration has differentiated oxygenator devices used in extracorporeal circulation according to intended duration and use, while a 2023 safety communication highlighted operational consequences of device-quality failures.
- The Novalung ultimate kit received FDA 510(k) clearance under K232926 in April 2024, illustrating the importance of formal authorization for integrated extracorporeal systems.
- The Getinge Quadrox action discussed by the FDA showed that a packaging-related concern can interrupt supply, force hospitals to qualify substitutes, and impose costly remediation on a supplier.
- U.S. pandemic-period data reported mean ECMO hospitalization costs of USD 967,647 and an average length of stay of 26 days, reflecting staffing, intensive care, anticoagulation, and disposable components.
- Germany's ZE2024-03 framework recognizes ECMO and percutaneous extracorporeal lung assist as reimbursable add-on services, while other systems rely on less predictable funding arrangements.
- In China, lower-cost domestic systems have helped reduce the reported cost of ECMO relative to Western settings, but this also increases pricing pressure for multinational suppliers.
- Oxygenator manufacturers must demonstrate biocompatibility, performance consistency, packaging integrity, and post-market control, which slows product-refresh cycles and raises the threshold for new competitors.
- Brevintel analysis indicates that clinical need becomes revenue only when a hospital can finance and operate an ECMO pathway safely, concentrating demand around tertiary institutions.
Segmentation Analysis
Type
- Hollow fiber membrane oxygenators generated USD 80.2 million in 2025, representing approximately 59.9% of market revenue, and are projected to reach USD 103.9 million by 2035 at an approximately 2.7% CAGR.
- Their growth premium reflects a central role in ECMO, where PMP hollow fiber membranes support extended gas exchange and are compatible with advanced blood-contacting surface treatments.
- Research on nitric oxide-releasing selenium-phosphorylcholine coatings has demonstrated antithrombotic and anti-inflammatory potential in ECMO-related applications.
- Separate research on phosphorylcholine-heparin composite coatings reported improved hemocompatibility indicators for artificial lung membranes.
- These coating developments remain research-stage evidence rather than proof of commercial performance, but they explain why surface technology is strategically relevant to premium platforms.
- Flat sheet membrane oxygenators accounted for USD 53.6 million in 2025 and are forecast to reach USD 63.7 million by 2035 at an approximately 1.8% CAGR.
- Slower flat sheet growth is consistent with the migration of prolonged support toward hollow fiber systems.
- Flat sheet designs retain demand in selected short-duration cardiac-surgery and specialized extracorporeal applications, where operational familiarity and lower system complexity can outweigh long-duration performance requirements.
Application
- The respiratory segment is valued at USD 61.0 million in 2025, representing approximately 45.6% of market revenue, and is expected to reach USD 74.4 million by 2035 at an approximately 2.1% CAGR.
- Respiratory failure is the largest respiratory subsegment, rising from USD 22.0 million to USD 27.8 million at an approximately 2.4% CAGR.
- Pulmonary embolism is projected to increase from USD 17.4 million to USD 21.4 million at an approximately 2.2% CAGR.
- ARDS is forecast to rise from USD 13.3 million in 2025 to USD 15.8 million in 2035 at an approximately 1.8% CAGR.
- Pneumonia grows from USD 8.3 million to USD 9.5 million at an approximately 1.4% CAGR, reflecting selective ECMO use after conventional management fails.
- Cardiac applications are estimated at USD 45.5 million in 2025 and are projected to reach USD 56.6 million by 2035 at an approximately 2.3% CAGR.
- Decompensated cardiomyopathy is the largest cardiac subsegment, increasing from USD 15.7 million to USD 19.0 million at an approximately 2.1% CAGR.
- Acute myocardial infarction is the fastest-growing cardiac subsegment, advancing from USD 12.6 million to USD 16.4 million at an approximately 2.7% CAGR.
- Cardiogenic shock is projected to expand from USD 10.0 million to USD 12.7 million at an approximately 2.5% CAGR.
- Post-transplant complications increase from USD 5.1 million to USD 6.1 million at an approximately 1.8% CAGR, and myocarditis rises from USD 2.2 million to USD 2.4 million at an approximately 1.1% CAGR.
- ECPR is projected to be the fastest-growing application, increasing from USD 27.3 million in 2025 to USD 36.5 million in 2035 at an approximately 3.0% CAGR.
- A comparative meta-analysis found lower in-hospital mortality associated with ECPR than conventional CPR, including in the in-hospital cardiac-arrest subgroup, while also reporting better long-term neurological outcomes.
Age group and end use
- Adults account for USD 85.5 million in 2025, or approximately 63.9% of market revenue, and are expected to reach USD 112.1 million by 2035 at an approximately 2.8% CAGR.
- Adult dominance reflects cardiogenic shock, acute myocardial infarction, respiratory failure, and cardiac arrest, and it benefits from ECPR growth concentrated in adult emergency and cardiac-care pathways.
- The neonatal segment is valued at USD 31.4 million in 2025 and is forecast to reach USD 36.6 million by 2035 at an approximately 1.6% CAGR.
- A 2023 trial evaluated an infant and pediatric oxygenator in surgical neonates receiving ECMO, illustrating highly specific clinical and technical requirements.
- Pediatrics account for USD 17.0 million in 2025 and are projected to reach USD 18.9 million by 2035 at an approximately 1.2% CAGR.
- Hospitals represent the largest end-use segment at USD 59.0 million in 2025, or approximately 44.1% of revenue, and are projected to reach USD 77.8 million by 2035 at an approximately 2.9% CAGR.
- Fresenius Medical Care's November 2024 agreement with Premier extended negotiated access to the Novalung ECMO System across Premier's U.S. member network.
- Ambulatory surgical centers account for USD 45.0 million in 2025 and are forecast to reach USD 54.7 million by 2035 at an approximately 2.1% CAGR, linked primarily to shorter-duration perfusion and cardiac-surgery workflows.
- Other end users generated USD 29.8 million in 2025 and are projected to reach USD 35.0 million by 2035 at an approximately 1.7% CAGR, including specialized transport, research, and extracorporeal blood-management settings.
- A European geospatial analysis found that timely access to extracorporeal life support remains uneven across participating countries, indicating that hospital-based capacity expansion can create new demand where access gaps persist.
Regional Outlook
North America and Europe
- North America is estimated at USD 47.2 million in 2025, representing approximately 35.2% of global revenue, and is projected to reach USD 54.8 million by 2035 at an approximately 1.6% CAGR.
- The U.S. market increases from USD 44.4 million to USD 51.1 million at an approximately 1.5% CAGR, while Canada rises from USD 2.7 million to USD 3.7 million at an approximately 3.1% CAGR.
- Slower North American growth reflects market maturity rather than weak demand: established ECMO centers, reimbursement pathways, and FDA-cleared product availability already support high utilization.
- Further growth depends more on procedure intensity and protocol expansion than on widespread formation of new programs, and supply assurance has become a procurement consideration alongside clinical familiarity.
- Europe is forecast to expand from USD 36.8 million in 2025 to USD 45.0 million in 2035 at an approximately 2.1% CAGR.
- Germany, France, the UK, Spain, Italy, and the Netherlands form the covered market base, supported by reimbursement structures, established cardiac programs, and regional ECMO networks.
- Germany's ECMO and PECLA add-on reimbursement framework provides a clearer funding mechanism than many other markets, while center concentration can constrain the number of purchasing sites.
- North America and much of Europe are utilization-led markets, where established centers drive demand through protocol intensity, supply continuity, and contracted purchasing.
Asia Pacific, Latin America, and Middle East & Africa
- Asia Pacific is projected to be the fastest-growing region, advancing from USD 35.9 million in 2025 to USD 49.3 million in 2035 at an approximately 3.3% CAGR.
- China, Japan, India, Australia, and South Korea are included in the regional scope, with growth driven by expansion of ECMO availability, particularly in China, rather than only higher utilization at mature centers.
- China's reported expansion into additional hospitals and the emergence of domestic ECMO products are reducing access barriers while introducing material price competition.
- Japan retains deep technical experience in membrane oxygenator development, while South Korea's improving pediatric ECMO outcomes indicate expanding clinical maturity; India and Australia contribute through tertiary critical-care and transplant capacity.
- Latin America is estimated at USD 8.9 million in 2025 and is projected to reach USD 11.7 million by 2035 at an approximately 2.9% CAGR, with Brazil and Mexico anchoring demand and Argentina contributing through tertiary hospital activity.
- Latin American growth begins from a smaller installed base and is limited by device-import exposure, uneven reimbursement, and shortages of specialized personnel.
- The Middle East and Africa market is projected to grow from USD 5.1 million in 2025 to USD 6.7 million in 2035 at an approximately 2.9% CAGR, with South Africa, Saudi Arabia, and the UAE as the covered markets.
- Asia Pacific, Latin America, and the Middle East and Africa depend more on program formation, reimbursement expansion, and trained clinical teams, making affordability, local service, and training support central in developing ECMO networks.
Competitive Landscape
Structure and recent developments
- Competition is defined by regulatory clearance, circuit integration, clinical familiarity, surface technology, and the ability to maintain supply to high-acuity programs.
- The approved company scope comprises Abbott, BRAILE, chalice, CytoSorbents, EUROSETS, Fresenius, GETINGE, LivaNova, Medtronic, MicroPort, NIPRO, PrecisionMedical, RECTUS MEDICAL, TERUMO, and XENIOS.
- Abbott participates in pediatric-focused extracorporeal support applications, reinforced by clinical evaluation of an infant and pediatric oxygenator in neonatal ECMO settings.
- BRAILE serves adult cardiac and respiratory applications, with particular relevance to Brazilian hospital and cardiac-surgery procurement.
- chalice markets PMP hollow fiber oxygenator configurations for adult and neonatal cardiac use; the FDA cleared its CMO8 Adult PMP Oxygenator with Tubing Pack under K231414 in November 2023.
- CytoSorbents participates through blood-purification technology that can be used alongside extracorporeal circuits, addressing inflammatory-mediator management rather than conventional oxygenation alone.
- EUROSETS offers ECMO-focused oxygenator systems across adult, neonatal, and pediatric care, and its AMG PMP oxygenator has been included in comparative oxygenator dysfunction analysis.
- On November 19, 2024, Fresenius Medical Care announced a group purchasing agreement with Premier for the Novalung ECMO System for Mechanical Circulatory Support.
- The FDA issued a June 2023 letter to healthcare providers concerning oxygenator devices used for extracorporeal circulation after Getinge/Maquet actions related to potentially compromised packaging sterility.
- The FDA cleared the Novalung ultimate kit under 510(k) K232926 in April 2024, covering a pre-connected extracorporeal circuit configuration designed for respiratory and cardiopulmonary support, including specified adult indications.
- Peer-reviewed studies published in 2023 and 2025 examined phosphorylcholine-based, heparin-containing, and nitric oxide-releasing surface strategies intended to improve blood compatibility in artificial lung membranes.
- Once an ECMO program standardizes a circuit configuration, switching costs include retraining, protocol revision, and supply-continuity risk rather than simply the price of an individual oxygenator.
Integrated producers
- Abbott
- LivaNova
- Medtronic
- MicroPort
- NIPRO
- Fresenius
- GETINGE
- TERUMO
Specialty suppliers
- BRAILE
- chalice
- CytoSorbents
- EUROSETS
- PrecisionMedical
- RECTUS MEDICAL
- XENIOS